[1] Global Initiative for Asthma. Global strategy for asthma management and prevention(updated 2015)[R]. . Global strategy for asthma management and prevention(updated 2015)[R]. http://www.ginasthma.org.
[2] 苏楠, 林江涛, 王文雅, 等. 我国八省市重症支气管哮喘患病情况的现状分析[J]. 中华内科杂志,2016,55(12):917-921.
[3] 冯晓凯, 林江涛, 苏楠, 等. 我国14岁以上人群支气管哮喘患病危险因素的调查分析[J]. 中华医学杂志,2014,94(16):1209-1214.
[4] Chung KF, Wenzel SE, Brozek JL, et al.International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma[J]. Eur Respir J,2014,43(2):343-373.
[5] Hoskins G, McCowan C, Neville RG, et al. Risk factors and costs associated with an asthma attack[J]. Thorax,2000,55(1):19-24.
[6] 林江涛, 冯晓凯. 应高度重视支气管哮喘的疾病负担研究[J]. 中华医学杂志,2014,94(16):1201-1203.
[7] 林江涛. 努力提高我国难治性哮喘的防治和研究水平[J]. 中华结核和呼吸杂志,2010,33(8):561-562.
[8] Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations,unanswered questions. American Thoracic Society[J]. Am J Respir Crit Care Med,2000,162(6):2341-2351.
[9] Chung KF, Godard P, Adelroth E, et al.Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society[J]. Eur Respir J,1999,13(5):1198-1208.
[10] 中华医学会呼吸病学分会哮喘学组. 难治性哮喘诊断与处理专家共识[J]. 中华结核和呼吸杂志,2010,33(8):572-577.
[11] Chung KF.New treatments for severe treatment-resistant asthma: targeting the right patient[J]. Lancet Respir Med,2013,1(8):639-652.
[12] 中华医学会呼吸病学分会哮喘学组, 中国哮喘联盟. 重症哮喘诊断与处理中国专家共识[J]. 中华结核和呼吸杂志,2017,40(11):813-829.
[13] Vazquez-Tello A, Semlali A, Chakir J, et al.Induction of glucocorticoid receptor-beta expression in epithelial cells of asthmatic airways by T-helper type 17 cytokines[J]. Clin Exp Allergy,2010,40(9):1312-1322.
[14] Rosmond R.The glucocorticoid receptor gene and its association to metabolic syndrome[J]. Obes Res,2002,10(10):1078-1086.
[15] Panek M, Pietras T, Fabijan A, et al.Effect of glucocorticoid receptor gene polymorphisms on asthma phenotypes[J]. Exp Ther Med,2013,5(2):572-580.
[16] Yang N, Ray DW, Matthews LC.Current concepts in glucocorticoid resistance[J]. Steroids,2012,77(11):1041-1049.
[17] Sun LC, Lin JT, Li W, et al.Nicotine inhibits histone deacetylase 6 activity and chaperone-dependent activation of the glucocorticoid receptor in A549 cells[J]. Chin Med J (Engl),2012,125(4):662-666.
[18]
[19] 郝敏, 林江涛. 糖皮质激素不敏感的分子机制研究进展[J]. 中华医学杂志,2014,94(26):2073-2075.
[20] Aaron SD, Vandemheen KL, Boulet LP, et al.Overdiagnosis of asthma in obese and nonobese adults[J]. CMAJ,2008,179(11):1121-1131.
[21] Robinson DS, Campbell DA, Durham SR, et al.Systema-tic assessment of difficult-to-treat asthma[J]. Eur Respir J,2003,22(3):478-483.
[22] Barranco P, Pérez-Francés C, Quirce S, et al.Consensus document on the diagnosis of severe uncontrolled asthma[J]. J Investig Allergol Clin Immunol,2012,22(7):460-475.
[23] ten Brinke A, Zwinderman AH, Sterk PJ, et al. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids[J]. Am J Respir Crit Care Med,2004,170(6):601-605.
[24] Ortega HG, Liu MC, Pavord ID, et al.Mepolizumab treatment in patients with severe eosinophilic asthma[J]. N Engl J Med,2014,371(13):1198-1207.
[25] Bel EH, Wenzel SE, Thompson PJ, et al.Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma[J]. N Engl J Med,2014,371(13):1189-1197.
[26] Danek CJ, Lombard CM, Dungworth DL, et al.Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs[J]. J Appl Physiol (1985),2004,97(5):1946-1953.
[27] Cox G, Thomson NC, Rubin AS, et al.Asthma control during the year after bronchial thermoplasty[J]. N Engl J Med,2007,356(13):1327-1337.
